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Abstract
Background Growth differentiation factor-15 (GDF-15)
may be a biomarker of disease, protective response and/or
prognosis, in older people with hypertension.
Aims To correlate baseline GDF-15 levels with physical
and vascular health data in this population.
Methods Baseline blood samples were analysed using a
GDF-15 ELISA assay kit. Correlations with baseline and
12-month outcome data, including measures of physical
and vascular function, were performed.
Results A total of 147 individuals, mean age
76.8 ± 4.7 years, were included. 77 (52 %) were male.
Baseline log10GDF-15 showed significant correlations with
age (r = 0.37, p\ 0.001), total cholesterol (r = -0.33,
p\ 0.001) and 6-min walking distance (r = -0.37,
p\ 0.001). Age remained significantly associated with
log10GDF-15 in multivariable analysis (beta = -0.29,
p = 0.001). Baseline log10GDF-15 was significantly asso-
ciated with decline in 6-min walk distance over 12 months
(beta = -0.27, p = 0.01) in multivariable models. No
significant correlations were seen with changes in vascular
function over 12 months.
Conclusion Baseline GDF-15 predicts declining physical,
but not vascular, function in our population.
Keywords Ageing  Biomarker  Cardiovascular disease 
Frailty  Inflammation
Introduction
The decline in physical function that commonly accom-
panies ageing is multifactorial in aetiology. Impairments in
multiple organ systems, including muscle, nerve, bone,
blood vessels and the brain, all contribute to this loss in
function. Cardiovascular disease (CVD) in particular is a
common cause of hospital admissions amongst older
patients and is also a key driver of functional decline.
Functional loss, and the accompanying vulnerability to
stressors, is captured in the concept of frailty [1]. It is clear
that in order to effectively manage frailty, an approach that
protects, or bolsters function, across multiple organ sys-
tems—i.e. an approach that builds resilience—is necessary
[2]. For such an approach to be practical, interventions that
target common pathologies affecting multiple organ sys-
tems are required; targets such as chronic inflammation,
oxidative stress and mitochondrial dysfunction are exam-
ples of this. Both CVD and sarcopenia (the age-related
decline in muscle function) have been linked to chronic
inflammation. Effective interventions may be best
deployed early in the process of decline, and to detect those
at risk, markers that predict decline before the onset of
frailty would be useful.
GDF-15 may represent a potential biomarker of age-
related disease. Discovered in 1997, it is classified struc-
turally as a divergent member of the transforming growth
factor b (TGF-b) superfamily of cytokines [3]. This family
comprises both pro- and anti-inflammatory molecules
implicated in diverse inflammatory and fibrotic conditions.
Activated macrophages produce GDF-15, and it is believed
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to serve a self-regulatory function by limiting macrophage
activation. It is ubiquitously expressed, and levels rise with
age, perhaps reflecting its role in regulating cell prolifera-
tion, apoptosis and repair, all of which constitute basic
cellular stress responses [4, 5]. It may also affect energy
metabolism and storage [6], showing correlations with
BMI, inflammatory conditions (e.g. rheumatoid arthritis)
and malignancies [7, 8]. A persistent, low-grade pro-in-
flammatory state is thought to be a key pathophysiological
mechanism underlying ageing [9]. Given this, and the
potentially protective role that GDF-15 might have in
inflammatory regulation (10), it may provide a novel can-
didate biomarker for predicting functional decline across
multiple organ systems.
We therefore tested whether GDF-15 was (a) associated
with baseline measures of vascular and physical function
and (b) predicted future decline in vascular and physical
function, in a cohort of older patients with isolated systolic
hypertension.
Methods
We conducted analyses using samples and data collected
prospectively as part of the vitamin D in isolated systolic
hypertension (VitDISH) randomised controlled trial, which
tested the effect of vitamin D supplementation on blood
pressure in patients aged 70 and over with isolated systolic
hypertension [10]. Participants were randomised into
VitDISH if they had a baseline systolic BP of[140 mmHg
but\180 mmHg, a baseline diastolic BP of\90 mmHg
and a baseline 25OHD level of\75 nmol/L. Participants
received 100,000 units of oral vitamin D3 or placebo every
3 months for a year in the trial, which showed no signifi-
cant effect of vitamin D supplementation on any outcome
measured. The trial was approved by the Fife and Forth
Valley National Health Service Research Ethics Commit-
tee [10].
Outcome measurements from the VitDISH trial avail-
able for this analysis were BMI, office systolic and dias-
tolic blood pressure, B-type natriuretic peptide, C-reactive
protein, serum-adjusted calcium, glucose, cholesterol,
parathyroid hormone and 25OHD levels, submaximal
exercise capacity measured using the 6-min walk, hospital
anxiety and depression scores (HADS), endothelial func-
tion measured using brachial artery flow-mediated dilata-
tion (FMD), and carotid-radial pulse wave velocity using
the Sphygmocor system as a measure of arterial stiffness.
Baseline demographic data included age, gender and a past
medical history of the following conditions: diabetes mel-
litus, myocardial infarction, angina, peripheral vascular
disease and stroke/TIA.
Stored baseline serum samples were used for GDF-15
assays. Samples were allowed to clot at room temperature
for 15 min, then spun at 3000 rpm for 10 min and stored in
freezers (-20C) for between three and a half to 5 years.
GDF-15 was measured in duplicate using a Quantikine
ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA).
The mean intra-assay coefficient of variation (CV) was
4.4 %, and the inter-assay CV was 19.8 %.
All statistical analyses were performed using IBM
SPSS Statistics version 22.0 (IBM, New York, USA).
Significance was defined as a two-sided p < 0.05. Base-
line population characteristics are presented as frequen-
cies and proportions, mean values with standard
deviations or as medians with inter-quartile ranges
(Table 1). As GDF-15, CRP and BNP levels were not
normally distributed, results were log-transformed prior to
analysis to enable parametric testing. Associations
between baseline variables were examined using Pear-
son’s correlation coefficient for continuous variables, and
with Student’s t-test for dichotomous variable. Multi-
variable linear regression models were used to determine
associations between baseline log10GDF-15 levels
and other baseline variables, and between baseline
log10GDF-15 levels and changes in measures of vascular
and physical health between baseline and 12 months.
Both unadjusted and adjusted analyses were performed,
with adjustment for baseline variables likely to influence
either vascular health or physical function. The adjusted
models were run both with and without age as a covariate,
in case the strong correlation between age and log10GDF-
15 masked a potentially important association.
Results
Sufficient stored baseline samples were available for
147/159 participants, who had been randomised to VitD-
ISH. Analyses were conducted on 146 of thesre, as one
sample was excluded due to [30 % difference between
duplicates on GDF-15 testing. Table 1 shows the baseline
population characteristics for these individuals, along with
baseline associations between each variable and log10GDF-
15 levels. Baseline log10GDF-15 levels were significantly
associated with increasing age, total cholesterol levels,
diastolic BP and HADS depression scores. Independent
sample t-tests showed significantly higher baseline log10-
GDF-15 in males, and those with a history of diabetes,
myocardial infarction and angina. No significant associa-
tions were demonstrated with baseline measures of vas-
cular function. Baseline multivariable linear regression
showed GDF-15 levels remained associated only with age
(beta = 0.29, p\ 0.001).
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Baseline GDF-15 correlated significantly with 12-month
changes in LDL cholesterol (r = 0.06, p = 0.019) and
6-min walk distance (r = 0.23, p = 0.009), but not with
other measures. Multivariable linear regression (Table 2)
showed that higher baseline GDF-15 was associated with
steeper decline in 6-min walk distance at 12 months after
adjustment, but no relationship with changes in blood
pressure, nor markers of vascular health, was evident.
Discussion
Our results suggest that in older patients with hypertension,
GDF-15 may be an independent predictor of declining
physical function, but does not predict change in vascular
function. Whilst our investigation supported previous
associations of GDF-15 levels with cardiovascular risk
factors and the presence of vascular disease, the responsi-
ble mechanisms are not clear, as no correlation was seen
between GDF-15 and endothelial function nor arterial
stiffness (two key pathophysiological intermediaries for
causing vascular disease).
The lack of correlation between GDF-15 and both
endothelial function and arterial stiffness may be explained
by numerous factors. Firstly, both FMD and PWV measure
macrovascular, rather than microvascular, function. The
PIVUS study also noted no correlation with brachial artery
FMD, but observed significant correlations between GDF-
15 and endothelium-dependent and endothelium-indepen-
dent microvascular vasodilatation [11]. Another proposed
pathway linking GDF-15 to CVD is the phosphoinositide
3-kinase (PI3k)/protein kinase Cf (PKCf)/specificity pro-
tein 1 (SP1) pathway [12]. This increases ABCA1 gene
expression and causing greater macrophage cholesterol
Table 1 Baseline details and univariate associations with GDF-15 levels (n = 146) [11]
Factor Baseline level Correlation versus log10GDF-15 p for correlation
Mean age (years) (SD) 76.8 (4.7) 0.37* \0.001
Body mass index (Kg/m2) (SD) 28.2 (4.8) 0.03 0.69
Median baseline GDF-15 (pg/mL) (IQR) 400 (246) – –
Systolic blood pressure (mmHg) (SD) 162 (11) 0.01 0.91
Diastolic blood pressure (mmHg) (SD) 78 (7) -0.17* 0.04
Adjusted calcium (mmol/L) (SD) 2.31 (0.07) -0.07 0.42
Glucose (mmol/L) (SD) 5.3 (0.8) 0.10 0.26
Total cholesterol (mmol/L) (SD) 4.9 (1.1) -0.33* \0.001
Parathyroid Hormone (pmol/L) (SD) 5.4 (2.5) 0.07 0.42
Median C-reactive protein (mg/L) (IQR) 1.7 (0.8 – 3.9) 0.04 0.63
Median BNP (pg/mL) (IQR) 31 (14 – 81) 0.11 0.18
25OHD (nmol/L) (SD) 44 (15) -0.11 0.17
Pulse wave velocity (m/s) (SD) 8.8 (1.2) -0.03 0.71
FMD of brachial artery (%) (SD) 5.2 (2.7) 0.06 0.51
Mean HADS score (anxiety) (SD) 4.2 (2.7) -0.03 0.69
Mean HADS score (depression) (SD) 3.4 (2.4) 0.26* 0.001
Six-minute walking distance (m) (SD) 402 (99) -0.37* \0.001
Mean log10GDF-15
Present versus absent
p for comparison
Male, N. (%) 77 (52) 2.63 versus 2.56* 0.01
Diabetes mellitus, N. (%) 17 (12) 2.74 versus 2.58* \0.001
Myocardial infarction, N. (%) 9 (6) 2.74 versus 2.59* 0.02
Angina/PTCA/CABG, N. (%) 33 (22) 2.66 versus 2.58* 0.02
Peripheral vascular disease, N. (%) 10 (7) 2.63 versus 2.60 0.66
Stroke/TIA, N. (%) 16 (11) 2.64 versus 2.59 0.33
BNP b-type natriuretic peptide, CABG coronary artery bypass graft, FMD flow-mediated dilatation GDF-15 growth differentiation factor-15,
HADS hospital anxiety and depression score, HDL high-density lipoprotein, IQR interquartile range, LDL low-density lipoprotein, PTCA
percutaneous transluminal coronary angioplasty, SD standard deviation, TIA transient ischaemic attack
* p\ 0.05
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efflux, perhaps limiting foam cell formation to confer
atherosclerosis protection. This is substantiated by the
correlations between GDF-15 and cholesterol levels evi-
denced by both our results and those of previous studies
[11, 13]. Finally, the macrovascular disease mechanisms in
older people (for example, the relevance of vascular cal-
cification) may not be associated with GDF-15 in the same
way as changes seen in previously studied younger cohorts.
GDF-15 is an autocrine inhibitor of inflammation,
released in response to pro-inflammatory cytokines such as
IL-6 or TNF-a [14]. However, its mechanisms of action
remain unclear due to the broad diversity of its functions
[14]. Unlike traditional anti-inflammatory pathways,
detailed molecular knowledge of GDF-15 signalling
remains sparse and deserves further exploration. The pre-
viously well-established positive correlation between GDF-
15 and age was corroborated by our results [13]. Numerous
age-related conditions (atherosclerosis, chronic kidney
disease, obesity and diabetes, cancer and cognitive
impairment) are also associated with elevated GDF-15,
making it a clinically relevant biomarker. Gene expression
studies on hNAG-18 have shown that GDF-15 may influ-
ence age-associated pathology development through
mechanisms related to obesity, appetite, insulin sensitivity,
energy metabolism and mTOR activity [6]. These complex
interactions represent pathways that may be implicated in
the development of sarcopenia (reduced muscle strength
and functional ability), which can impair physical function
in old age. Excessively elevated GDF-15 levels, as seen in
chronic inflammatory conditions, cancer and ageing, can
cause cachexia. These effects seem to be mediated via
neurones (in the hypothalamus and area postrema and
nucleus tractus solitarius of the brainstem) that regulate
appetite [15], and ERK1 and 2, neuropeptide Y and mel-
anocortin signalling [16], confirming the role of protein-
wasting and sarcopenia in contributing to worsening 6-min
walking distances.
It is also important to acknowledge the potential effects
of pre-existing risk factors and co-morbidities on physical
function. Our results showed that those with higher baseline
GDF-15 levels were more likely to be male, and have a past
medical history of diabetes mellitus, myocardial infarction
and/or ischaemic heart disease. Given the large degree of
overlap between these demographics and GDF-15 levels, it
is currently impossible to extricate the effects of each
individual factor. Moreover, the lifestyle factors associated
with these conditions (such as lack of exercise, poor diet
and smoking), and the restrictions on exercise tolerance and
activity levels that accompany conditions such as ischaemic
heart disease, are also likely to limit physical function.
Despite this assortment of contributory factors, it is possible
that GDF-15 may serve as a unifying, objective marker for
their cumulative effect on physical function.
Strengths, limitations and future work
Our analysis is strengthened by the availability of detailed
phenotypic data on a range of vascular, physical and psy-
chological measures, and by the availability of 1-year
follow-up data on most participants, enabling adjustment
for several important confounders.
However, a number of limitations deserve comment.
The study population was limited by its size and by all
participants being of white ethnicity. We therefore cannot
assume that they are representative of the wider elderly
population. The age of our cohort and the presence of
hypertension inevitably limit the scope for correlation
analyses to detect links between measures of vascular
function and GDF-15 levels, due to the limited range of
these variables. A population-based study would likely
increase the range of FMD, PWV and GDF-15 values,
enhancing the ability to detect associations. Moreover, a
wider panel of dependent variables (including measures of
microvascular function and frailty—e.g. weight loss, grip
Table 2 Association of baseline log10GDF-15 Levels with 12-month changes in vascular and physical health
Variable Unadjusted Adjusted model excluding agea Adjusted model including agea
Beta p Beta p Beta p
Systolic blood pressure 0.02 0.87 -0.11 0.30 -0.11 0.28
Diastolic blood pressure 0.02 0.80 -0.14 0.17 -0.16 0.14
Pulse wave velocity -0.06 0.56 -0.04 0.65 -0.05 0.64
FMD of brachial artery -0.03 0.78 0.04 0.55 0.05 0.54
B-type natriuretic peptide 0.10 0.43 0.06 0.75 0.05 0.78
Six-minute walk distance -0.15 0.11 -0.26* 0.02 -0.27* 0.01
FMD flow-mediated dilatation, GDF growth differentiation factor
* p\ 0.05
a Adjusted for baseline vascular disease, blood pressure, cholesterol, FMD, PWV, BNP, glucose, calcium, PTH, CRP, 25OHD, 6-min walk and
sex
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strength, sit–stand time and ability to carry out activities of
daily living) would be of considerable value in future
studies. Studying other clinical outcomes such as time to
hospital readmission or mortality data would also be of
interest. However, meaningful analysis of such outcomes
will require larger study sample sizes and longer follow-up
than was available for this analysis.
Knowledge of the biological mechanisms of action of
GDF-15 remains incomplete. Future studies should attempt
not only to determine whether GDF-15 predicts adverse
outcomes in a wider range of older people, but to ascertain
whether GDF-15 is part of a causal pathway leading to
sarcopenia and dysfunction of other organ systems, whe-
ther raised GDF-15 levels actively contribute to protective
responses to pathology, or whether raised levels are a
bystander marker of other pathological processes (e.g.
oxidative stress or other inflammatory signals). Finally, the
effect of interventions known to improve physical function
(e.g. exercise training) on GDF-15 levels may help answer
these questions.
Conclusion
Baseline GDF-15 may be associated with walk distance
and predicts decline in walk distance, but is not associated
with vascular function in older patients with hypertension.
These findings may enable the development of new ways to
detect those at risk of functional decline, as well as sug-
gesting new pathways to target the inflammatory causes
and consequences of ageing.
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